---
title: "Touyun Biotech Group First Half 2025 Earnings: EPS: HK$0.007 (vs HK$0.013 loss in 1H 2024)"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/257983886.md"
description: "Touyun Biotech Group reported its First Half 2025 earnings, showing an EPS of HK$0.007, a recovery from a loss of HK$0.013 in 1H 2024. Revenue decreased by 34% to HK$31.5 million, while net income improved to HK$19.4 million from a loss of HK$35.5 million in the previous year. The profit margin rose to 62%. However, shares have declined by 15% over the past week, and the company faces significant investment risks with four warning signs identified."
datetime: "2025-09-18T22:30:37.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/257983886.md)
  - [en](https://longbridge.com/en/news/257983886.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/257983886.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/257983886.md) | [English](https://longbridge.com/en/news/257983886.md)


# Touyun Biotech Group First Half 2025 Earnings: EPS: HK$0.007 (vs HK$0.013 loss in 1H 2024)

## Touyun Biotech Group (HKG:1332) First Half 2025 Results

### Key Financial Results

-   Revenue: HK$31.5m (down 34% from 1H 2024).
-   Net income: HK$19.4m (up from HK$35.5m loss in 1H 2024).
-   Profit margin: 62% (up from net loss in 1H 2024).
-   EPS: HK$0.007 (up from HK$0.013 loss in 1H 2024).

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

SEHK:1332 Earnings and Revenue History September 18th 2025

_All figures shown in the chart above are for the trailing 12 month (TTM) period_

Touyun Biotech Group shares are down 15% from a week ago.

### Risk Analysis

It's necessary to consider the ever-present spectre of investment risk. **We've identified 4 warning signs** with Touyun Biotech Group (at least 3 which are significant), and understanding these should be part of your investment process.

### 相關股票

- [TOUYUN BIOTECH (01332.HK)](https://longbridge.com/zh-HK/quote/01332.HK.md)

## 相關資訊與研究

- [The AI Backlash, or, The Hollywood Revolution That Fizzled](https://longbridge.com/zh-HK/news/281659358.md)
- [10:00 ETSanyou Milestone | Recognized as a "Shanghai Municipal Enterprise Technology Center," Further Validating for Innovation Excellence](https://longbridge.com/zh-HK/news/281035304.md)
- [CATL's controlling shareholder to donate some A-shares](https://longbridge.com/zh-HK/news/281197776.md)
- [Nepal holds its first post-poll parliament session](https://longbridge.com/zh-HK/news/281506765.md)
- [10:19 ETVascarta Announces Positive Clinical Trial Results for Topical/Transdermal Curcumin Gel VAS-101 in Knee Osteoarthritis](https://longbridge.com/zh-HK/news/281386093.md)